Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
Most Recent Events
- 10 Oct 2022 Status changed from active, no longer recruiting to completed.
- 25 Mar 2022 Planned End Date changed from 7 Mar 2022 to 15 Apr 2022.
- 25 Mar 2022 Planned primary completion date changed from 7 Mar 2022 to 15 Apr 2022.